Novartis Corporation Edges Ahead of Merck KGaA in MS Race; Novartis's Lower Dose of FTY720 Filed for U.S. and EU Approval; Merck's Cladribine Faces FDA Delay
Reuters -- Swiss drugmaker Novartis has edged ahead of German rival Merck KGaA in the race to get the first oral multiple sclerosis treatment to market, having now filed for approval in the United States and Europe.